|
1
|
International Agency for Research on
Cancer (IARC): Latest world cancer statistics, Global cancer burden
rises to 14.1 million new cases in 2012: Marked increase in breast
cancers must be addressed. Press Release 223. 2013, https://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf.
Accessed December 12, 2013.
|
|
2
|
International Agency for Research on
Cancer (IARC): GLOBOCAN: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. 2012, http://globocan.iarc.fr/Default.aspx.
|
|
3
|
Greaves M and Maley CC: Clonal evolution
in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suzuki HI, Katsura A, Matsuyama H and
Miyazono K: MicroRNA regulons in tumor microenvironment. Oncogene.
34:3085–3094. 2015. View Article : Google Scholar
|
|
5
|
Scheel C, Onder T, Karnoub A, Weinberg RA
and Talmadge JE: Adaptation versus selection: The origins of
metastatic behavior. Cancer Res. 67:11476–11479; discussion
11479–11480. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
9
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scheel C, Eaton EN, Li SH, Chaffer CL,
Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, et al:
Paracrine and autocrine signals induce and maintain mesenchymal and
stem cell states in the breast. Cell. 145:926–940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beck B, Lapouge G, Rorive S, Drogat B,
Desaedelaere K, Delafaille S, Dubois C, Salmon I, Willekens K,
Marine JC, et al: Different levels of Twist1 regulate skin tumor
initiation, stemness, and progression. Cell Stem Cell. 16:67–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo M, Brooks M and Wicha MS:
Epithelial-mesenchymal plasticity of breast cancer stem cells:
Implications for metastasis and therapeutic resistance. Curr Pharm
Des. 21:1301–1310. 2015. View Article : Google Scholar :
|
|
14
|
Medema JP: Cancer stem cells: The
challenges ahead. Nat Cell Biol. 15:338–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
16
|
Mongroo PS and Rustgi AK: The role of the
miR-200 family in epithelial-mesenchymal transition. Cancer Biol
Ther. 10:219–222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eger A, Aigner K, Sonderegger S, Dampier
B, Oehler S, Schreiber M, Berx G, Cano A, Beug H and Foisner R:
DeltaEF1 is a transcriptional repressor of E-cadherin and regulates
epithelial plasticity in breast cancer cells. Oncogene.
24:2375–2385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Howe EN, Cochrane DR and Richer JK: The
miR-200 and miR-221/222 microRNA families: Opposing effects on
epithelial identity. J Mammary Gland Biol Neoplasia. 17:65–77.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zuo ZH, Yu YP, Ding Y, Liu S, Martin A,
Tseng G and Luo JH: Oncogenic activity of miR-650 in prostate
cancer is mediated by suppression of CSR1 expression. Am J Pathol.
185:1991–1999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng L, Xie Y, Zhang H and Wu Y:
Down-regulation of NDRG2 gene expression in human colorectal cancer
involves promoter methylation and microRNA-650. Biochem Biophys Res
Commun. 406:534–538. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeng ZL, Li FJ, Gao F, Sun DS and Yao L:
Upregulation of miR-650 is correlated with down-regulation of ING4
and progression of hepatocellular carcinoma. J Surg Oncol.
107:105–110. 2013. View Article : Google Scholar
|
|
24
|
Chan E, Patel R, Nallur S, Ratner E,
Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M,
et al: MicroRNA signatures differentiate melanoma subtypes. Cell
Cycle. 10:1845–1852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu
Z and Zhang M: MicroRNA-650 targets ING4 to promote gastric cancer
tumorigenicity. Biochem Biophys Res Commun. 395:275–280. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim S, Chin K, Gray JW and Bishop JM: A
screen for genes that suppress loss of contact inhibition:
Identification of ING4 as a candidate tumor suppressor gene in
human cancer. Proc Natl Acad Sci USA. 101:16251–16256. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang F, Luo LB, Tao YM, Wu F and Yang LY:
Decreased expression of inhibitor of growth 4 correlated with poor
prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers
Prev. 18:409–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li R, Yu C, Jiang F, Gao L, Li J, Wang Y,
Beckwith N, Yao L, Zhang J and Wu G: Overexpression of N-Myc
downstream-regulated gene 2 (NDRG2) regulates the proliferation and
invasion of bladder cancer cells in vitro and in vivo. PLoS One.
8:e766892013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qu H, Yin H, Yan S, Tao M, Xie Y and Chen
W: Inhibitor of growth 4 suppresses colorectal cancer growth and
invasion by inducing G1 arrest, inhibiting tumor angiogenesis and
reversing epithelial-mesenchymal transition. Oncol Rep.
35:2927–2935. 2016.PubMed/NCBI
|
|
30
|
Wang CJ, Yang D and Luo YW: Recombinant
ING4 suppresses the migration of SW579 thyroid cancer cells via
epithelial to mesenchymal transition. Exp Ther Med. 10:603–607.
2015.PubMed/NCBI
|
|
31
|
Shen L, Qu X, Ma Y, Zheng J, Chu D, Liu B,
Li X, Wang M, Xu C, Liu N, et al: Tumor suppressor NDRG2 tips the
balance of oncogenic TGF-β via EMT inhibition in colorectal cancer.
Oncogenesis. 3:e862014. View Article : Google Scholar
|
|
32
|
Lee DG, Lee SH, Kim JS, Park J, Cho YL,
Kim KS, Jo DY, Song IC, Kim N, Yun HJ, et al: Loss of NDRG2
promotes epithelial-mesenchymal transition of gallbladder carcinoma
cells through MMP-19-mediated Slug expression. J Hepatol.
63:1429–1439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim MJ, Lim J, Yang Y, Lee MS and Lim JS:
N-myc downstream-regulated gene 2 (NDRG2) suppresses the
epithelial-mesenchymal transition (EMT) in breast cancer cells via
STAT3/Snail signaling. Cancer Lett. 354:33–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun B, Pu B, Chu D, Chu X, Li W and Wei D:
MicroRNA-650 expression in glioma is associated with prognosis of
patients. J Neurooncol. 115:375–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mraz M, Dolezalova D, Plevova K, Stano
Kozubik K, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S,
Borsky M, et al: MicroRNA-650 expression is influenced by
immunoglobulin gene rearrangement and affects the biology of
chronic lymphocytic leukemia. Blood. 119:2110–2113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yun JH, Moon S, Lee HS, Hwang MY, Kim YJ,
Yu HY, Kim Y, Han BG, Kim BJ and Kim JM: MicroRNA-650 in a copy
number-variable region regulates the production of interleukin 6 in
human osteosarcoma cells. Oncol Lett. 10:2603–2609. 2015.PubMed/NCBI
|
|
37
|
Huang JY, Cui SY, Chen YT, Song HZ, Huang
GC, Feng B, Sun M, De W, Wang R and Chen LB: MicroRNA-650 was a
prognostic factor in human lung adenocarcinoma and confers the
docetaxel chemoresistance of lung adenocarcinoma cells via
regulating Bcl-2/Bax expression. PLoS One. 8:e726152013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Eastham AM, Spencer H, Soncin F, Ritson S,
Merry CL, Stern PL and Ward CM: Epithelial-mesenchymal transition
events during human embryonic stem cell differentiation. Cancer
Res. 67:11254–11262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Steinestel K, Eder S, Schrader AJ and
Steinestel J: Clinical significance of epithelial-mesenchymal
transition. Clin Transl Med. 3:172014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gunduz M, Nagatsuka H, Demircan K, Gunduz
E, Cengiz B, Ouchida M, Tsujigiwa H, Yamachika E, Fukushima K,
Beder L, et al: Frequent deletion and down-regulation of ING4, a
candidate tumor suppressor gene at 12p13, in head and neck squamous
cell carcinomas. Gene. 356:109–117. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang QS, Li M, Zhang LY, Jin Y, Tong DD,
Yu Y, Bai J, Huang Q, Liu FL, Liu A, et al: Down-regulation of ING4
is associated with initiation and progression of lung cancer.
Histopathology. 57:271–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Garkavtsev I, Kozin SV, Chernova O, Xu L,
Winkler F, Brown E, Barnett GH and Jain RK: The candidate tumour
suppressor protein ING4 regulates brain tumour growth and
angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Byron SA, Min E, Thal TS, Hostetter G,
Watanabe AT, Azorsa DO, Little TH, Tapia C and Kim S: Negative
regulation of NF-κB by the ING4 tumor suppressor in breast cancer.
PLoS One. 7:e468232012. View Article : Google Scholar
|
|
46
|
Li M, Zhu Y, Zhang H, Li L, He P, Xia H,
Zhang Y and Mao C: Delivery of inhibitor of growth 4 (ING4) gene
significantly inhibits proliferation and invasion and promotes
apoptosis of human osteosarcoma cells. Sci Rep. 4:73802014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shen JC, Unoki M, Ythier D, Duperray A,
Varticovski L, Kumamoto K, Pedeux R and Harris CC: Inhibitor of
growth 4 suppresses cell spreading and cell migration by
interacting with a novel binding partner, liprin alpha1. Cancer
Res. 67:2552–2558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li J and Li G: Cell cycle regulator ING4
is a suppressor of melanoma angiogenesis that is regulated by the
metastasis suppressor BRMS1. Cancer Res. 70:10445–10453. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hong SN, Kim SJ, Kim ER, Chang DK and Kim
YH: Epigenetic silencing of NDRG2 promotes colorectal cancer
proliferation and invasion. J Gastroenterol Hepatol. 31:164–171.
2016. View Article : Google Scholar
|
|
50
|
Kim YJ, Kang HB, Yim HS, Kim JH and Kim
JW: NDRG2 positively regulates E-cadherin expression and prolongs
overall survival in colon cancer patients. Oncol Rep. 30:1890–1898.
2013.PubMed/NCBI
|
|
51
|
Kim MJ, Kim HS, Lee SH, Yang Y, Lee MS and
Lim JS: NDRG2 controls COX-2/PGE(2)-mediated breast cancer cell
migration and invasion. Mol Cells. 37:759–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Faraji SN, Mojtahedi Z, Ghalamfarsa G and
Takhshid MA: N-myc downstream regulated gene 2 overexpression
reduces matrix metalloproteinase-2 and -9 activities and cell
invasion of A549 lung cancer cell line in vitro. Iran J Basic Med
Sci. 18:773–779. 2015.PubMed/NCBI
|
|
53
|
Golestan A, Mojtahedi Z, Ghalamfarsa G,
Hamidinia M and Takhshid MAP: The effects of NDRG2 overexpression
on cell proliferation and invasiveness of SW48 colorectal cancer
cell line. Iran J Med Sci. 40:430–439. 2015.
|
|
54
|
Kreso A and Dick JE: Evolution of the
cancer stem cell model. Cell Stem Cell. 14:275–291. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
57
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nieto MA: Epithelial-mesenchymal
transitions in development and disease: Old views and new
perspectives. Int J Dev Biol. 53:1541–1547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shipitsin M, Campbell LL, Argani P,
Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T,
Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of
breast tumor heterogeneity. Cancer Cell. 11:259–273. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Santisteban M, Reiman JM, Asiedu MK,
Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC,
Manjili MH, et al: Immune-induced epithelial to mesenchymal
transition in vivo generates breast cancer stem cells. Cancer Res.
69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dave B, Mittal V, Tan NM and Chang JC:
Epithelial-mesenchymal transition, cancer stem cells and treatment
resistance. Breast Cancer Res. 14:2022012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Davis FM, Stewart TA, Thompson EW and
Monteith GR: Targeting EMT in cancer: Opportunities for
pharmacological intervention. Trends Pharmacol Sci. 35:479–488.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Krause M, Dubrovska A, Linge A and Baumann
M: Cancer stem cells: Radioresistance, prediction of radiotherapy
outcome and specific targets for combined treatments. Adv Drug
Deliv Rev. Feb 12–2016.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kloten V, Schlensog M, Eschenbruch J,
Gasthaus J, Tiedemann J, Mijnes J, Heide T, Braunschweig T, Knüchel
R and Dahl E: Abundant NDRG2 expression is associated with
aggressiveness and unfavorable patients' outcome in basal-like
breast cancer. PLoS One. 11:e01590732016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zheng J, Li Y, Yang J, Liu Q, Shi M, Zhang
R, Shi H, Ren Q, Ma J, Guo H, et al: NDRG2 inhibits hepatocellular
carcinoma adhesion, migration and invasion by regulating CD24
expression. BMC Cancer. 11:251–259. 1–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Grange C, Tapparo M, Collino F, Vitillo L,
Damasco C, Deregibus MC, Tetta C, Bussolati B and Camussi G:
Microvesicles released from human renal cancer stem cells stimulate
angiogenesis and formation of lung premetastatic niche. Cancer Res.
71:5346–5356. 2011. View Article : Google Scholar : PubMed/NCBI
|
